ReviewJournal of clinical medicine2021
Fertility-Sparing Surgery for Ovarian Cancer.
Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 49 citations in OpenAlex.
- Review
- Controlled Ovarian Stimulation After Fertility-Sparing Surgery for Borderline Ovarian Tumors: An Exploratory Cohort Study on Recurrence and Reproductive Outcomes.Current oncology (Toronto, Ont.) · 2026Article
- Frequency of optimal and sub-optimal fertility-sparing surgery in young women with ovarian cancer: A single-center observational cohort study.Pakistan journal of medical sciences · 2026Article
- From Preservation to Creation: The Expanding Frontier of Fertility Preservation - Proceedings of the 2Facts, views & vision in ObGyn · 2026Article
- Computed Tomography Angiography-Assisted Ovarian Vein Sampling for Diagnosing an Androgen-Producing Leydig Cell Tumor: A Case Report.Case reports in endocrinology · 2026Article
- Three-Dimensional Bioprinting and Infertility-Related Female Reproductive System Diseases: A Review of Current and Future Applications.Tissue engineering and regenerative medicine · 2025Review
- The Oncological Follow-Up of Fertility Sparing Surgery for Mucinous Borderline Ovarian Tumours: A Retrospective Cohort Study.Cancers · 2025Article
- Clinicopathological Characteristics and Oncologic Outcomes of Endometrioid Ovarian Carcinoma: A Retrospective Study from a Tertiary Cancer Centre.Biomedicines · 2025Article
- Ovarian Collision Tumor in a Pediatric Patient: A Mature Teratoma Associated with a Combined Tumor Containing a Mucinous Cystadenocarcinoma Component.Journal of clinical medicine · 2025Article
- Mucinous Ovarian Carcinoma: Integrating Molecular Stratification into Surgical and Therapeutic Management.Biomedicines · 2025Review
- How to Preserve Fertility in Reproductive-Age Women with Cancer.Journal of clinical medicine · 2025Review
- Fertility Sparing Medical Management Options in Gynecologic Cancers.Current treatment options in oncology · 2025Review
- Review
- Mucinous Carcinoma of Ovary in a 15-Year-Old Girl, A Rare Case Report and Literature Review.Turk patoloji dergisi · 2025Review
- Real Implication of Fertility-Sparing Surgery for Ovarian Cancer: Reproductive Outcomes.Diagnostics (Basel, Switzerland) · 2024Article
- A Comprehensive Review of Current Trends in the Diagnosis and Treatment of Ovarian Germ Cell Tumors.Cureus · 2024Review
- Article
- Could uterine conservation be an option in presumed early-stage epithelial ovarian cancer?Archives of gynecology and obstetrics · 2023Article
- Fertility-sparing surgery: a hopeful strategy for young women with cancer.Journal of medicine and life · 2023Review
- Reproductive and oncologic outcomes in women with non-epithelial ovarian cancer: Single center experience over 25 years.Turkish journal of obstetrics and gynecology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
(1) Background: although most patients with epithelial ovarian cancer (EOC) undergo radical surgery, patients with early-stage disease, borderline ovarian tumor (BOT) or a non-epithelial tumor could be offered fertility-sparing surgery (FSS) depending on histologic subtypes and prognostic factors. (2) Methods: we conducted a systematic review to assess the safety and fertility outcomes of FSS in the treatment of ovarian cancer. We queried the MEDLINE, PubMed, Cochrane Library, and Cochrane ("Cochrane Reviews") databases for articles published in English or French between 1985 and 15 January 2021. (3) Results: for patients with BOT, FSS should be offered to young women with a desire to conceive, even if peritoneal implants are discovered at the time of initial surgery. Women with mucinous BOT should undergo initial unilateral salpingo-oophorectomy, whereas cystectomy is an acceptable option for women with serous BOT. Assisted reproductive technology (ART) can be initiated in patients with stage I BOT if infertility persists after surgery. For patients with EOC, FSS should only be considered after staging for women with stage IA grade 1 (and probably 2, or low-grade in the current classification) serous, mucinous or endometrioid tumors. FSS could also be offered to patients with stage IC grade 1 (or low-grade) disease. For women with serous, mucinous or endometrioid high-grade stage IA or low-grade stage IC1 or IC2 EOC, bilateral salpingo-oophorectomy and uterine conservation could be offered to allow pregnancy by egg donation. Finally, FSS has a large role to play in patients with non- epithelial ovarian cancer, and particularly women with malignant ovarian germ cell tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.